Document Detail


Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis.
MedLine Citation:
PMID:  19388879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Chinese herbal therapy is sometimes used in conjunction with transcatheter arterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC) in Asian countries. This study aims to systemically review the efficacy of Chinese herbal therapy in HCC patients receiving TACE. METHODS: Meta-analysis was performed for clinical trials comparing Chinese herbal therapy versus no Chinese herbal therapy given to HCC patients receiving TACE. Publications in 10 electronic databases were extensively searched. RESULTS/CONCLUSION: Chinese herbal therapy was associated with a significant rise in the number of patients with survival > 1-year, 2-year and 3-year, as well as a significant rise in the number of patients who reported complete or partial response and non-deterioration performance status. Chinese herbal therapy also showed significant efficacies in the increase of T cells and natural killer cells, whereas a significant lower blood alpha-fetoprotein concentration was reported. There were a significant increase in white blood cell count, a significant lower risk in patients with nausea and vomiting, and a significant rise in patients with increased body weight when Chinese herbal therapy was given. The evidence from this review supports the use of Chinese herbal therapy to enhance the efficacy of TACE in HCC patients. However, owing to limited data and heterogeneity of the included studies, further trials are required.
Authors:
William Cs Cho; Hai-Yong Chen
Related Documents :
11051369 - Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a vali...
20572309 - Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular ca...
20713179 - A 30-year, population-based study shows improved management and prognosis of hepatocell...
15654659 - A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection a...
10522859 - Hepatectomy for hepatocellular carcinoma: the surgeon's role in long-term survival.
2538259 - A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge ...
3955519 - Conservative treatment (chemotherapy/radiotherapy) of locally advanced breast cancer.
22524919 - Accuracy of prognostic scores in decision making and predicting outcomes in metastatic ...
11561609 - Combined-modality therapy in pancreatic cancer: current status and future directions.
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  18     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-04-24     Completed Date:  2010-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  617-35     Citation Subset:  IM    
Affiliation:
Queen Elizabeth Hospital, Department of Clinical Oncology, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong. chocs@ha.org.hk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / administration & dosage*
Carcinoma, Hepatocellular / drug therapy*,  mortality
Chemoembolization, Therapeutic / methods*
Combined Modality Therapy
Drugs, Chinese Herbal / administration & dosage*
Humans
Liver Neoplasms / drug therapy*,  mortality
Randomized Controlled Trials as Topic / methods
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Drugs, Chinese Herbal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent developments in the treatment of uveitis: an update.
Next Document:  VEGF inhibitors for the treatment of neovascular age-related macular degeneration.